VF
AKTX

Virtu Financial’s Akari Therapeutics AKTX Stock Holding History

Virtu Financial’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-563
Closed -$22K – 1608
2025
Q3 		$22K Buy
+563
New +$21.9K ﹤0.01% 1265
2023
Q3 		– Sell
-21
Closed -$3K – 1245
2023
Q2 		$3K Buy
+21
New +$3.04K ﹤0.01% 1417
2023
Q1 		– Sell
-13
Closed -$5K – 1489
2022
Q4 		$5K Buy
+13
New +$5.38K ﹤0.01% 1445
2022
Q2 		– Sell
-21
Closed -$20K – 1534
2022
Q1 		$20K Buy
+21
New +$22.2K ﹤0.01% 1296
2020
Q3 		– Sell
-23
Closed -$40K – 1008
2020
Q2 		$40K Buy
+23
New +$35K ﹤0.01% 1035
2019
Q4 		– Sell
-39
Closed -$53K – 1405
2019
Q3 		$53K Buy
39
+25
+179% +$38.3K ﹤0.01% 1184
2019
Q2 		$22K Sell
14
-36
-72% -$80.5K ﹤0.01% 1336
2019
Q1 		$143K Buy
+50
New +$95.4K 0.01% 1071
2018
Q3 		– Sell
-37
Closed -$58K – 1499
2018
Q2 		$58K Buy
+37
New +$58.1K ﹤0.01% 1734

Other funds holding AKTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $309M AUM
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Virtu Financial's AKTX Position: Q4 2025 in Review

Virtu Financial sold out of Akari Therapeutics (AKTX) in Q4 2025, closing a stake of 563 shares — an estimated $22K sold.

Virtu Financial first reported a position in AKTX in Q2 2018 and held it in 9 quarters. The position peaked at $143K in Q1 2019. 19 funds tracked by Wall St. Rank hold AKTX as of Q4 2025.

  • Virtu Financial reported no remaining Akari Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Virtu Financial sold 563 Akari Therapeutics shares in Q4 2025, an estimated $22K.
  • Virtu Financial first reported a position in Akari Therapeutics in Q2 2018 and held it in 9 quarters.
  • Virtu Financial's Akari Therapeutics position peaked at $143K in Q1 2019.
  • 19 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2025.

Based on Virtu Financial's 13F filing for Q4 2025, filed 23 Feb 2026.